Vanda Pharmaceuticals is ending the year on a high note, securing FDA approval of its oral NK-1 receptor antagonist Nereus (tradipitant) to prevent vomiting induced by motion, with a market launch anticipated in the coming months."For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options," remarked Mihael Polymeropoulos, chief executive of Vanda.The approval, announc